GASTROINTESTINAL STROMAL TUMORS
Clinical trials for GASTROINTESTINAL STROMAL TUMORS explained in plain language.
Never miss a new study
Get alerted when new GASTROINTESTINAL STROMAL TUMORS trials appear
Sign up with your email to follow new studies for GASTROINTESTINAL STROMAL TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for GIST patients: drug combo targets resistant tumors
Disease control OngoingThis study tests a combination of two drugs, bezuclastinib and sunitinib, in 40 adults with advanced gastrointestinal stromal tumors (GIST) that continued to grow despite sunitinib treatment alone. The goal is to see if the combination can slow cancer progression and to identify …
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for rare stomach cancer? drug targets specific mutations
Disease control OngoingThis early study tests the drug regorafenib in 3 adults with a rare stomach and intestinal cancer called GIST. Only people with certain gene changes (KIT exon 17, 18, or 14, or SDHB deficiency) whose cancer got worse after imatinib can join. The goal is to see if regorafenib can …
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug ripretinib takes on standard therapy for Hard-to-Treat GIST cancer
Disease control OngoingThis study tests a new drug called ripretinib against the current standard sunitinib in people with advanced gastrointestinal stromal tumor (GIST) whose cancer worsened or who couldn't tolerate the first treatment imatinib. About 453 adults from multiple countries will take eithe…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New combo tackles resistant gut tumors in early trial
Disease control OngoingThis early-phase study tests a new drug (TAS-116) combined with imatinib in people with advanced gastrointestinal stromal tumors (GIST) that no longer respond to imatinib alone. About 78 participants will receive different treatments to find the safest dose and see if the combo c…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:39 UTC